See more : Data Storage Corporation (DTST) Income Statement Analysis – Financial Results
Complete financial analysis of Gilead Sciences, Inc. (GILD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gilead Sciences, Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Coach A Co., Ltd. (9339.T) Income Statement Analysis – Financial Results
- IHS Markit Ltd. (0UAI.L) Income Statement Analysis – Financial Results
- Capital Small Finance Bank Limited (CAPITALSFB.NS) Income Statement Analysis – Financial Results
- Northstar Gold Corp. (NSGCF) Income Statement Analysis – Financial Results
- Sabre Insurance Group plc (SBRE.L) Income Statement Analysis – Financial Results
Gilead Sciences, Inc. (GILD)
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.12B | 27.28B | 27.31B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B | 11.20B | 9.70B | 8.39B | 7.95B | 7.01B | 5.34B | 4.23B | 3.03B | 2.03B | 1.32B | 867.86M | 466.79M | 233.77M | 195.56M | 169.00M | 32.60M | 40.00M | 33.40M | 2.70M | 4.10M | 4.20M | 2.80M | 1.30M |
| Cost of Revenue | 6.50B | 5.66B | 6.60B | 4.57B | 4.68B | 4.85B | 4.37B | 4.26B | 4.01B | 3.79B | 2.86B | 2.47B | 2.12B | 1.87B | 1.60B | 1.13B | 768.77M | 433.32M | 260.33M | 166.59M | 112.69M | 69.72M | 43.76M | 21.50M | 16.90M | -2.20M | -1.80M | -3.60M | -3.20M | -2.80M | -1.70M | -1.00M | -800.00K |
| Gross Profit | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B | 28.63B | 21.10B | 8.34B | 7.23B | 6.26B | 6.08B | 5.42B | 4.21B | 3.46B | 2.59B | 1.77B | 1.16B | 755.17M | 397.07M | 190.01M | 174.05M | 152.10M | 34.80M | 41.80M | 37.00M | 5.90M | 6.90M | 5.90M | 3.80M | 2.10M |
| Gross Profit Ratio | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | 85.68% | 87.17% | 87.42% | 87.02% | 85.06% | 81.28% | 89.00% | 90.00% | 106.75% | 104.50% | 110.78% | 218.52% | 168.29% | 140.48% | 135.71% | 161.54% |
| Research & Development | 6.92B | 4.98B | 5.36B | 5.04B | 9.11B | 5.02B | 3.73B | 5.10B | 3.01B | 2.85B | 2.12B | 1.76B | 1.23B | 1.07B | 939.92M | 721.77M | 591.03M | 383.86M | 277.72M | 223.55M | 164.87M | 134.76M | 185.55M | 131.57M | 112.90M | 75.30M | 59.20M | 41.90M | 0.00 | 26.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.26B | 4.90B | 4.51B | 4.36B | 3.60B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 826.00M | 778.00M | 735.00M | 795.00M | 784.00M | 587.00M | 600.00M | 618.00M | 601.00M | 393.00M | 216.00M | 160.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 34.70M | 7.60M | 22.40M | 9.10M | 6.10M |
| Other Expenses | 0.00 | -581.00M | -639.00M | -1.42B | 1.87B | 676.00M | 523.00M | 428.00M | 154.00M | 3.00M | -8.89M | -37.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.22M | 0.00 | 0.00 | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| Operating Expenses | 13.67B | 10.65B | 10.61B | 10.19B | 13.49B | 9.07B | 7.61B | 8.50B | 6.44B | 5.84B | 3.82B | 3.22B | 2.47B | 2.12B | 1.89B | 1.53B | 1.30B | 957.52M | 656.97M | 526.35M | 425.25M | 316.06M | 310.69M | 226.37M | 203.80M | 109.10M | 87.70M | 73.10M | 37.90M | 36.40M | 24.10M | 10.10M | 6.90M |
| Cost & Expenses | 19.69B | 16.31B | 17.21B | 14.76B | 18.16B | 13.93B | 11.98B | 12.76B | 10.45B | 9.63B | 6.68B | 5.69B | 4.60B | 3.99B | 3.48B | 2.66B | 2.07B | 1.39B | 917.30M | 692.93M | 537.94M | 385.78M | 354.46M | 247.87M | 220.70M | 106.90M | 85.90M | 69.50M | 34.70M | 33.60M | 22.40M | 9.10M | 6.10M |
| Interest Income | 0.00 | 935.00M | 1.00B | 984.00M | 995.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.58M | 60.29M | 42.40M | 59.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M | 688.00M | 412.00M | 306.89M | 360.92M | 205.42M | 108.96M | 69.66M | 12.10M | 0.00 | 4.67B | 0.00 | 0.00 | 996.28M | 23.66M | 0.00 | 6.12M | 37.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 344.70M | 278.21M | 302.23M | 265.48M | 212.94M | 102.47M | 51.28M | 47.28M | 35.78M | 24.41M | 20.86M | 14.43M | 14.69M | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| EBITDA | 10.50B | 8.85B | 11.33B | 4.13B | 7.56B | 10.31B | 15.93B | 19.22B | 23.45B | 16.32B | 4.86B | 4.25B | 4.16B | 4.29B | 3.78B | 2.84B | 2.22B | -576.83M | 1.15B | 688.18M | 350.78M | 81.01M | -106.00M | -40.31M | -39.10M | -65.10M | -56.90M | -31.60M | -28.80M | -31.30M | -16.50M | -5.30M | -4.00M |
| EBITDA Ratio | 38.71% | 38.10% | 34.63% | 34.46% | 27.42% | 40.11% | 56.10% | 59.43% | 68.47% | 61.34% | 40.31% | 40.95% | 45.99% | 50.60% | 50.94% | 51.47% | 52.38% | 134.71% | 56.54% | 48.54% | 97.90% | 23.88% | -116.58% | -19.15% | -9.05% | -275.77% | -153.00% | -139.52% | -1,259.26% | -753.66% | -495.24% | -257.14% | -369.23% |
| Operating Income | 7.61B | 7.33B | 7.41B | 7.03B | 4.29B | 8.20B | 14.12B | 17.63B | 22.19B | 15.27B | 4.52B | 4.01B | 3.79B | 3.96B | 3.53B | 2.68B | 2.16B | -758.75M | 1.11B | 631.69M | -158.68M | 81.01M | -120.69M | -52.32M | -51.70M | -74.30M | -45.90M | -36.10M | -32.00M | -29.50M | -18.20M | -6.30M | -4.80M |
| Operating Income Ratio | 28.05% | 26.87% | 27.12% | 28.47% | 19.10% | 37.06% | 54.10% | 58.02% | 68.00% | 61.33% | 40.39% | 41.33% | 45.20% | 49.84% | 50.34% | 50.20% | 51.17% | -25.07% | 54.78% | 47.69% | -18.28% | 17.35% | -51.63% | -26.75% | -30.59% | -227.91% | -114.75% | -108.08% | -1,185.19% | -719.51% | -433.33% | -225.00% | -369.23% |
| Total Other Income/Expenses | -746.00M | -1.52B | 872.00M | -2.40B | 873.00M | -401.00M | -595.00M | -536.00M | -534.00M | -409.00M | -315.78M | -398.20M | -138.84M | -48.67M | -27.27M | -5.84M | 105.83M | 120.55M | 50.69M | 24.73M | -8.86M | -7.61M | 178.14M | 10.41M | -13.90M | 22.40M | -500.00K | 15.00M | 5.20M | 9.90M | 4.30M | 1.90M | 800.00K |
| Income Before Tax | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B | 21.66B | 14.86B | 4.21B | 3.61B | 3.65B | 3.91B | 3.50B | 2.73B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 57.45M | -41.91M | -65.60M | -55.90M | -27.60M | -21.10M | -26.80M | -25.30M | -13.90M | -4.40M | -4.00M |
| Income Before Tax Ratio | 25.30% | 21.31% | 30.32% | 6.76% | 22.99% | 35.25% | 51.82% | 56.26% | 66.36% | 59.69% | 37.57% | 37.23% | 43.54% | 49.23% | 49.95% | 51.25% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.57% | -21.43% | -38.82% | -171.47% | -69.00% | -63.17% | -992.59% | -617.07% | -330.95% | -157.14% | -307.69% |
| Income Tax Expense | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.89B | 3.61B | 3.55B | 2.80B | 1.15B | 1.04B | 861.95M | 1.02B | 876.36M | 723.25M | 655.04M | 551.75M | 347.88M | 207.05M | -95.53M | 1.30M | 4.14M | 1.20M | 900.00K | -36.60M | -36.20M | -29.40M | -9.80M | -8.00M | -8.40M | -3.70M | -1.60M |
| Net Income | 5.67B | 4.59B | 6.23B | 89.00M | 5.39B | 5.46B | 4.63B | 13.50B | 18.11B | 12.10B | 3.07B | 2.59B | 2.80B | 2.90B | 2.64B | 2.01B | 1.62B | -1.19B | 813.91M | 449.37M | -72.00M | 72.10M | 52.27M | -56.78M | -66.50M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
| Net Income Ratio | 20.89% | 16.83% | 22.80% | 0.36% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.50% | 37.59% | 37.69% | 38.19% | -39.32% | 40.13% | 33.92% | -8.30% | 15.45% | 22.36% | -29.03% | -39.35% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
| EPS | 4.54 | 3.66 | 4.96 | 0.07 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 | 7.95 | 2.01 | 1.71 | 1.81 | 1.70 | 1.46 | 1.09 | 0.87 | -0.65 | 0.45 | 0.26 | -0.04 | 0.05 | 0.04 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | 4.50 | 3.64 | 4.93 | 0.07 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 | 7.35 | 1.81 | 1.64 | 1.78 | 1.66 | 1.41 | 1.05 | 0.84 | -0.65 | 0.43 | 0.25 | -0.04 | 0.04 | 0.03 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.51B | 1.55B | 1.71B | 1.81B | 1.84B | 1.86B | 1.84B | 1.82B | 1.73B | 1.61B | 1.56B | 1.52B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.69B | 1.58B | 1.58B | 1.75B | 1.87B | 1.92B | 1.93B | 1.84B | 1.90B | 1.86B | 1.61B | 1.65B | 1.62B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.
Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices
Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences will also be a player in the anti-obesity market....
Gilead Sciences: Buy This Bargain Before It's Gone
Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the company's HIV franchise amounted to about $4.75...
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to...
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
10 Great Dividend Stocks For The Next 10 Years
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and...
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.
Source: https://incomestatements.info
Category: Stock Reports